Portal Vein Thrombosis After Transarterial Embolization for Hepatocellular Carcinoma - PubMed (original) (raw)

Portal Vein Thrombosis After Transarterial Embolization for Hepatocellular Carcinoma

Marisa E Schwab et al. JAMA Surg. 2024.

No abstract available

Plain language summary

This cross-sectional study assesses the association between venous thrombosis and embolization in patients with hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Decker reported receiving personal fees from Moon Surgical, nonfinancial support from National Clinician Scholars Program, and salary support from the Veteran Affairs Medical Center outside the submitted work. No other disclosures were reported.

Figures

Figure 1.

Figure 1.. Development of Right Hepatic Vein Thrombosis After Transarterial Chemoembolization

A-F, Imaging depicts the development of right hepatic vein thrombosis. C, Arrowhead points to necrosis. D, Arrowhead points to thrombosis. E, Arrowhead points to biliary necrosis. After hypertrophy of the left liver remnant, the patient underwent left hepatectomy. TACE indicates transarterial chemoembolization.

Figure 2.

Figure 2.. Development of Portal Vein Thrombosis and Atrophy Hypertrophy Complex After Transarterial Chemoembolization

A-F, Imaging depicts portal venous thrombosis and atrophy hypertrophy complex. Arrowheads in panels C, E, and F point to portal vein thrombosis. The patient did not undergo surgical resection. TACE indicates transarterial chemoembolization.

References

    1. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187-1195. doi: 10.1016/j.jhep.2015.02.010 -DOI -PubMed
    1. Butcher DA, Brandis KJ, Wang H, et al. Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(3):621-631. doi: 10.1016/j.ejso.2021.09.017 -DOI -PubMed
    1. Ho EY, Cozen ML, Shen H, et al. ; HOVAS Group (Hepatocellular Carcinoma Treatment Outcome at VA San Francisco) . Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014;16(8):758-767. doi: 10.1111/hpb.12214 -DOI -PMC -PubMed
    1. World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi: 10.1001/jama.2013.281053 -DOI -PubMed
    1. de Baère T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181(3):695-700. doi: 10.2214/ajr.181.3.1810695 -DOI -PubMed

MeSH terms

LinkOut - more resources